In addition, olaparib (i.p., 50 mg/kg daily) also elicited strong T cell-mediated cytotoxicity in a Brca1-deficient ovarian cancer mouse model and a BRCA1- and TP53-deficient genetically engineered mouse model (GEMM) of triple-negative breast cancer (TNBC) [131, 145]. Here, BRCA1 is linked to ovarian carcinoma.